Get started
Author

Eileen Cannon

Observed name: E Cannon
OpenAlex ID: A5055504296
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation
2018 · Emily Beth Devine, Eleanor Perfetto, et al. · Journal of Comparative Effectiveness Research · 2
A New Initiative With Multiple Sponsors to Help Prepare Medical Students to Be Safe and Effective Prescribers
2015 · D Nierenberg, E Cannon · Clinical Pharmacology & Therapeutics · 1
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases
PDF
Proposals from the 2018 PhRMA Challenge Award Program
2019 · Eileen Cannon, Daryl Pritchard · Journal of Managed Care & Specialty Pharmacy
PDF
Works count: 7
Citation count: 95
H-index: 3
I10-index: 3
Year
Topic
Type